Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Eli Lilly (NYSE:LLY) announced that its financial results for Q1 2025, prepared under the U.S. generally accepted accounting ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...